APA (7th ed.) Citation

G, G., NA, P., M, O., JM, P., JP, R., M, F., . . . HP, E. (2024). A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia, 38(1), 58. https://doi.org/10.1038/s41375-023-02073-x

Chicago Style (17th ed.) Citation

G, Garcia-Manero, et al. "A Randomized Phase III Study of Standard Versus High-dose Cytarabine with or Without Vorinostat for AML." Leukemia 38, no. 1 (2024): 58. https://doi.org/10.1038/s41375-023-02073-x.

MLA (9th ed.) Citation

G, Garcia-Manero, et al. "A Randomized Phase III Study of Standard Versus High-dose Cytarabine with or Without Vorinostat for AML." Leukemia, vol. 38, no. 1, 2024, p. 58, https://doi.org/10.1038/s41375-023-02073-x.